Introduktion
Den här sidan ger en omfattande analys av den kända insiderhandelshistoriken för John L Higgins. Insiders är tjänstemän, styrelseledamöter eller betydande investerare i ett företag. Det är olagligt för insiders att göra affärer i sina företag baserat på specifik, icke-offentlig information. Detta betyder inte att det är olagligt för dem att göra några affärer i sina egna företag. De måste dock rapportera alla affärer till SEC via ett formulär 4. Trots dessa restriktioner tyder akademisk forskning på att insiders – i allmänhet – tenderar att överträffa marknaden i sina egna företag.
Genomsnittlig handelslönsamhet
Den genomsnittliga handelslönsamheten är den genomsnittliga avkastningen av alla köp på den öppna marknaden som insidern gjort under de senaste tre åren. För att beräkna detta undersöker vi alla oplanerade köp på öppen marknad som görs av insidern, exklusive alla affärer som markerats som en del av en 10b5-1-handelsplan. Vi beräknar sedan den genomsnittliga prestandan för dessa affärer under 3, 6 och 12 månader, med ett genomsnitt av var och en av dessa varaktigheter för att generera ett slutgiltigt resultatmått för varje affär. Slutligen tar vi ett genomsnitt av alla prestationsmått för att beräkna ett prestationsmått för insidern. Denna lista inkluderar endast insiders som har gjort minst tre affärer under de senaste två åren.
Om lönsamheten för denna insiderhandel är "N/A", så har insidern antingen inte gjort några köp på den öppna marknaden under de senaste tre åren, eller så är affärerna de har gjort för nya för att kunna beräkna ett tillförlitligt resultatmått.
Uppdateringsfrekvens: Dagligen
Företag med rapporterade insiderpositioner
SEC-anmälningarna visar att John L Higgins har rapporterat innehav eller affärer i följande företag:
Värdepapper | Titel | Senaste rapporterade innehav |
---|---|---|
US:TECH / Bio-Techne Corporation | Director | 65 236 |
US:OABI / OmniAb, Inc. | Director | 2 851 887 |
US:LGND / Ligand Pharmaceuticals Incorporated | Director | 417 695 |
US:BCRX / BioCryst Pharmaceuticals, Inc. | Director | 15 000 |
Hur man tolkar diagrammen
Följande diagram visar aktieutvecklingen för värdepapper efter varje icke-planerad handel på öppen marknad som görs av John L Higgins. Icke-planerad handel är affärer som inte gjordes som en del av en 10b5-1-handelsplan. Aktieutvecklingen visas som kumulativ procentuell förändring av aktiekursen. Till exempel, om en insiderhandel gjordes den 1 januari 2019, kommer diagrammet att visa den dagliga procentuella förändringen av värdepapperet fram till idag. Om aktiekursen skulle gå från $10 till $15 under denna tid, skulle den kumulativa procentuella förändringen i aktiekursen vara 50%. En förändring i priset från 10 USD till 20 USD skulle vara 100 % och en prisändring på 10 USD till 5 USD skulle vara -50 %.
I slutändan försöker vi avgöra hur nära insiders affärer korrelerar med överavkastning (positiv eller negativ) i aktiekursen för att se om insidern tar tid för sina affärer att dra nytta av insiderinformation. Tänk på situationen där en insider gjorde detta. I den här situationen förväntar vi oss antingen (a) positiv avkastning efter köp eller (b) negativ avkastning efter försäljning. I fallet med (a) skulle KÖP-diagrammet visa en serie uppåtlutande kurvor, vilket indikerar positiv avkastning efter varje köptransaktion. I fallet med (b) skulle SALE-diagrammet visa en serie nedåtlutande kurvor, vilket indikerar negativ avkastning efter varje försäljningstransaktion.
Detta är dock inte tillräckligt för att dra slutsatser. Om till exempel aktiekursen i bolaget var i en icke-cyklisk stigning under många år, skulle vi förvänta oss att alla tomter efter köpet skulle vara uppåtlutande. Likaså skulle icke-cykliska nedgångar under många år resultera i nedåtlutande post-trade tomter. Inget av dessa diagram skulle tyda på insiderhandel.
Den starkaste indikatorn skulle vara en situation där aktiekursen var extremt cyklisk, och det fanns både positiva signaler i KÖP-diagrammet och negativa plotter på SALE-diagrammet. Denna situation skulle i hög grad tyda på en insider som tog tid för affärer till sin ekonomiska fördel.
Insiderköp BCRX / BioCryst Pharmaceuticals, Inc. - Analys av kortsiktig vinst
I det här avsnittet analyserar vi lönsamheten för varje oplanerat insiderköp på en öppen marknad som görs i BCRX / BioCryst Pharmaceuticals, Inc.. Denna analys hjälper till att förstå om insidern konsekvent genererar onormal avkastning och är värd att följa. Denna analys är för ett år efter varje handel, och resultaten är teoretiska .
Tabellen nedan visar de senaste öppna marknadsköpen som inte var en del av en automatisk handelsplan.
Handelsdatum | Ticker | Insider | Rapporterade aktier |
Rapporterad pris |
Justerade aktier |
Justerat pris |
Kostnadsgrund | Dagar till max |
Pris vid max |
Max vinst ($) |
Maximal avkastning (%) |
---|---|---|---|---|---|---|---|
Det finns inga kända oplanerade öppna marknadstransaktioner för denna insider |
Det justerade prisetär det justerade priset efter split. Justerade aktier er de split-justerade aktier.
Insiderförsäljning - Analys av kortsiktig förlust
I det här avsnittet analyserar vi det kortsiktiga undvikandet av förluster för varje oplanerad insiderförsäljning på öppen marknad som görs i BCRX / BioCryst Pharmaceuticals, Inc.. Ett konsekvent mönster för att undvika förluster kan tyda på att framtida försäljningstransaktioner kan förutsäga prisnedgångar. Denna analys är för ett år efter varje handel, och resultaten är teoretiska .
Följande tabell visar de senaste försäljningarna på den öppna marknaden som inte ingick i en automatisk handelsplan.
Handelsdatum | Ticker | Insider | Rapporterade aktier |
Rapporterad pris |
Justerade aktier |
Justerat pris |
Kostnadsgrund | Dagar till min |
Pris vid min |
Maximal förlust undvikits ($) |
Maximal förlust undvikits ($) |
---|---|---|---|---|---|---|---|
Det finns inga kända oplanerade öppna marknadstransaktioner för denna insider |
Det justerade prisetär det justerade priset efter split. Justerade aktier er de split-justerade aktier.
Insiderhandelshistorik
Den här tabellen visar den fullständiga listan över insideraffärer gjorda av John L Higgins som avslöjats för Securities Exchange Commission (SEC).
Fildatum | Transaktionsdatum | Schema | Ticker | Värdepapper | Kode | Aktier | Återstående aktier | Procentuell förandring | Aktie pris |
Transaktionsvärde | Återstående värde |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-08-11 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
M - Exercise | 5 040 | 65 236 | 8,37 | 21,84 | 110 074 | 1 424 754 | |
2025-06-18 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
M - Exercise | 20 000 | 2 851 887 | 0,71 | ||||
2025-05-13 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
P - Purchase | 65 000 | 2 831 887 | 2,35 | 1,44 | 93 600 | 4 077 917 | |
2025-05-05 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
M - Exercise | 12 000 | 60 196 | 24,90 | 21,84 | 262 080 | 1 314 681 | |
2025-03-21 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
P - Purchase | 4 000 | 2 766 887 | 0,14 | 2,28 | 9 120 | 6 308 502 | |
2025-03-20 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
P - Purchase | 125 750 | 2 762 887 | 4,77 | 2,35 | 295 512 | 6 492 784 | |
2025-01-30 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
M - Exercise | 13 172 | 2 637 137 | 0,50 | ||||
2024-10-28 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
A - Award | 1 462 | 48 196 | 3,13 | ||||
2024-09-16 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
F - Taxes | −1 874 | 46 734 | −3,86 | 73,20 | −137 177 | 3 420 929 | |
2024-09-16 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
M - Exercise | 6 000 | 48 608 | 14,08 | 22,95 | 137 700 | 1 115 554 | |
2024-07-10 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
M - Exercise | 6 000 | 42 608 | 16,39 | 22,95 | 137 700 | 977 854 | |
2024-06-21 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
M - Exercise | 20 000 | 2 623 965 | 0,77 | ||||
2024-05-16 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
S - Sale | −4 000 | 36 608 | −9,85 | 83,84 | −335 377 | 3 069 372 | |
2024-05-16 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
M - Exercise | 4 000 | 40 608 | 10,93 | 22,95 | 91 800 | 931 954 | |
2024-04-23 |
|
4/A | OABI |
OmniAb, Inc.
Common Stock |
A - Award | 2 427 861 | 2 603 965 | 1 378,65 | ||||
2024-01-31 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
M - Exercise | 13 173 | 2 352 625 | 0,56 | ||||
2023-10-30 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
A - Award | 1 625 | 36 608 | 4,65 | ||||
2023-06-27 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
F - Taxes | 57 803 | 2 339 452 | 2,53 | 3,23 | 186 704 | 7 556 430 | |
2023-06-27 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
F - Taxes | 25 914 | 2 397 255 | 1,09 | 3,66 | 94 845 | 8 773 953 | |
2023-05-25 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
S - Sale | −9 000 | 2 462 686 | −0,36 | 4,05 | −36 450 | 9 973 878 | |
2023-05-25 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
M - Exercise | 9 000 | 2 471 686 | 0,37 | 3,68 | 33 120 | 9 095 804 | |
2023-05-23 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
S - Sale | −1 000 | 2 462 686 | −0,04 | 4,05 | −4 050 | 9 973 878 | |
2023-05-23 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
M - Exercise | 1 000 | 2 463 686 | 0,04 | 3,68 | 3 680 | 9 066 364 | |
2023-05-19 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
S - Sale | −50 000 | 2 462 686 | −1,99 | 3,89 | −194 500 | 9 579 849 | |
2023-05-19 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
M - Exercise | 50 000 | 2 512 686 | 2,03 | 3,68 | 184 000 | 9 246 684 | |
2023-05-02 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
F - Taxes | −4 377 | 34 983 | −11,12 | 79,88 | −349 635 | 2 794 442 | |
2023-05-02 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
M - Exercise | 16 000 | 39 360 | 68,49 | 21,85 | 349 600 | 860 016 | |
2023-02-01 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
A - Award | 39 517 | 2 462 686 | 1,63 | ||||
2022-12-30 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −5 289 | 417 695 | −1,25 | 66,29 | −350 608 | 27 689 002 | |
2022-12-20 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −10 000 | 422 984 | −2,31 | 61,87 | −618 657 | 26 168 201 |
2022-12-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
D - Sale to Issuer | −3 944 | 432 984 | −0,90 | 64,80 | −255 571 | 28 057 363 | |
2022-12-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 20 000 | 436 928 | 4,80 | 12,78 | 255 600 | 5 583 940 | |
2022-12-01 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −9 803 | 416 928 | −2,30 | 72,90 | −714 639 | 30 394 051 | |
2022-11-21 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 10 000 | 426 731 | 2,40 | 12,78 | 127 800 | 5 453 622 | |
2022-11-21 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −10 000 | 416 731 | −2,34 | 78,32 | −783 173 | 32 637 247 |
2022-11-03 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 45 922 | 424 731 | 12,12 | ||||
2022-11-03 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
M - Exercise | 246 648 | 2 423 169 | 11,33 | 2,52 | 621 553 | 6 106 386 | |
2022-11-03 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
A - Award | 2 176 521 | 2 176 521 | |||||
2022-10-31 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
A - Award | 338 | 5 840 | 6,14 | ||||
2022-09-22 |
|
4/A | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | −1 000 | 366 180 | −0,27 | 88,06 | −88 060 | 32 245 811 | |
2022-09-16 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | −3 000 | 364 180 | −0,82 | 89,35 | −268 050 | 32 539 483 | |
2022-09-16 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | −2 000 | 367 180 | −0,54 | 90,00 | −180 000 | 33 046 200 | |
2022-08-12 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
S - Sale | −8 | 5 502 | −0,15 | 380,71 | −3 046 | 2 094 666 | |
2022-08-12 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
S - Sale | −504 | 5 510 | −8,38 | 385,47 | −194 277 | 2 123 936 | |
2022-08-12 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
S - Sale | −992 | 6 014 | −14,16 | 380,15 | −377 112 | 2 286 240 | |
2022-08-12 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
S - Sale | −100 | 7 006 | −1,41 | 374,90 | −37 490 | 2 626 514 | |
2022-08-12 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
S - Sale | −900 | 7 106 | −11,24 | 373,99 | −336 593 | 2 657 586 | |
2022-08-12 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
M - Exercise | 3 400 | 8 006 | 73,82 | 66,90 | 227 460 | 535 601 | |
2022-07-06 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
J - Other | 164 | 369 180 | 0,04 | 75,84 | 12 437 | 27 997 504 | |
2022-06-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 20 423 | 369 016 | 5,86 | ||||
2022-06-09 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
S - Sale | −600 | 4 606 | −11,53 | 366,09 | −219 654 | 1 686 211 | |
2022-06-09 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
M - Exercise | 600 | 5 206 | 13,03 | 66,90 | 40 140 | 348 281 | |
2022-06-09 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
S - Sale | −1 000 | 4 606 | −17,84 | 364,31 | −364 310 | 1 678 012 | |
2022-06-09 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
M - Exercise | 1 000 | 5 606 | 21,71 | 66,90 | 66 900 | 375 041 | |
2022-05-10 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
0.75% Convertible Senior Notes due 2023 |
S - Sale | 429 159,38 | ||||||
2022-05-10 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
M - Exercise | −8 000 | 57 616 | −12,19 | ||||
2022-05-10 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 8 000 | 348 593 | 2,35 | 21,92 | 175 360 | 7 641 159 | |
2022-05-09 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
A - Award | 76 478 | 76 478 | |||||
2022-02-16 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −1 916 | 340 593 | −0,56 | 123,68 | −236 971 | 42 124 542 | |
2022-02-16 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −2 061 | 342 509 | −0,60 | 123,68 | −254 904 | 42 361 513 | |
2022-02-16 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −1 946 | 344 570 | −0,56 | 123,68 | −240 681 | 42 616 418 | |
2022-02-07 |
|
5 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
G - Gift | −2 502 | 332 593 | −0,75 | ||||
2022-01-28 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −6 183 | 349 018 | −1,74 | 113,68 | −702 883 | 39 676 366 | |
2022-01-28 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −3 060 | 355 201 | −0,85 | 113,68 | −347 861 | 40 379 250 | |
2022-01-28 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 13 560 | 358 261 | 3,93 | ||||
2022-01-28 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 9 606 | 344 701 | 2,87 | ||||
2021-11-12 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | −3 000 | 335 095 | −0,89 | 160,50 | −481 500 | 53 782 748 | |
2021-11-01 |
|
4 | TECH |
BIO-TECHNE Corp
Stock Option (right to buy) |
A - Award | 633 | 633 | |||||
2021-11-01 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
A - Award | 194 | 4 606 | 4,40 | ||||
2021-07-02 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
J - Other | 247 | 338 095 | 0,07 | 85,91 | 21 220 | 29 045 572 | |
2021-02-18 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −2 061 | 337 848 | −0,61 | 172,46 | −355 440 | 58 265 266 | |
2021-02-18 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −1 947 | 339 909 | −0,57 | 172,46 | −335 780 | 58 620 706 | |
2021-02-18 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −1 204 | 341 856 | −0,35 | 172,46 | −207 642 | 58 956 486 | |
2021-02-09 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −54 666 | 14 334 | −79,23 | |||
2021-02-09 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
M - Exercise | −60 000 | 0 | −100,00 | ||||
2021-02-09 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −2 970 | 343 060 | −0,86 | 203,03 | −602 999 | 69 651 472 | |
2021-02-09 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 60 000 | 346 030 | 20,98 | 10,05 | 603 000 | 3 477 602 | |
2021-02-09 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | −54 666 | 286 030 | −16,05 | 203,40 | −11 119 239 | 58 179 417 | |
2021-02-09 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | X | 54 666 | 340 696 | 19,11 | 14,47 | 791 017 | 4 929 871 |
2021-02-05 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
A - Award | 25 113 | 25 113 | |||||
2021-02-05 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 12 608 | 286 030 | 4,61 | ||||
2021-01-27 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
M - Exercise | −30 000 | 65 616 | −31,38 | ||||
2021-01-27 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −40 000 | 69 000 | −36,70 | |||
2021-01-27 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 30 000 | 273 422 | 12,32 | 21,92 | 657 600 | 5 993 410 | |
2021-01-27 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −40 000 | 243 422 | −14,11 | 182,00 | −7 280 000 | 44 302 804 |
2021-01-27 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | X | 40 000 | 283 422 | 16,43 | 14,47 | 578 800 | 4 101 116 |
2021-01-27 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −50 000 | 109 000 | −31,45 | |||
2021-01-27 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −4 596 | 243 422 | −1,85 | 156,01 | −717 022 | 37 976 266 | |
2021-01-27 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 9 607 | 248 018 | 4,03 | ||||
2021-01-27 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −2 845 | 238 411 | −1,18 | 156,01 | −443 848 | 37 194 500 | |
2021-01-27 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 5 946 | 241 256 | 2,53 | ||||
2021-01-27 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −50 000 | 235 310 | −17,52 | 159,00 | −7 950 000 | 37 414 290 |
2021-01-27 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | X | 50 000 | 285 310 | 21,25 | 14,47 | 723 500 | 4 128 436 |
2021-01-05 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
J - Other | 223 | 235 310 | 0,09 | 84,53 | 18 851 | 19 891 343 | |
2020-12-09 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
M - Exercise | −14 657 | 60 000 | −19,63 | ||||
2020-12-09 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −1 683 | 235 087 | −0,71 | 87,52 | −147 296 | 20 574 814 | |
2020-12-09 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 14 657 | 236 770 | 6,60 | 10,05 | 147 303 | 2 379 538 | |
2020-11-10 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
M - Exercise | −20 000 | 74 657 | −21,13 | ||||
2020-11-10 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −2 458 | 222 113 | −1,09 | 81,77 | −200 991 | 18 162 180 | |
2020-11-10 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 20 000 | 224 571 | 9,78 | 10,05 | 201 000 | 2 256 939 | |
2020-11-10 |
|
4 | TECH |
BIO-TECHNE Corp
Stock Option (Right to Buy) |
M - Exercise | −5 000 | 0 | −100,00 | ||||
2020-11-10 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
S - Sale | −3 100 | 4 412 | −41,27 | 301,06 | −933 301 | 1 328 297 | |
2020-11-10 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
S - Sale | −450 | 7 512 | −5,65 | 299,84 | −134 928 | 2 252 392 | |
2020-11-10 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
S - Sale | −1 450 | 7 962 | −15,41 | 298,98 | −433 516 | 2 380 451 | |
2020-11-10 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
M - Exercise | 5 000 | 9 412 | 113,33 | 70,35 | 351 750 | 662 134 | |
2020-11-02 |
|
4 | TECH |
BIO-TECHNE Corp
Stock Option (Right to Buy) |
A - Award | 1 507 | 1 507 | |||||
2020-11-02 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
A - Award | 391 | 4 412 | 9,72 | ||||
2020-07-09 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | −1 165 | 54 226 | −2,10 | ||||
2020-07-09 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | −1 373 | 93 627 | −1,45 | ||||
2020-07-09 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | −1 777 | 54 421 | −3,16 | ||||
2020-07-09 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 1 373 | 204 571 | 0,68 | 74,42 | 102 179 | 15 224 174 | |
2020-07-09 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 1 777 | 203 198 | 0,88 | 56,26 | 99 974 | 11 431 919 | |
2020-07-09 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 1 165 | 201 421 | 0,58 | 85,79 | 99 945 | 17 279 908 | |
2020-04-24 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −1 310 | 133 982 | −0,97 | 120,86 | −158 327 | 16 193 065 | |
2020-04-24 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −1 689 | 135 292 | −1,23 | 120,86 | −204 133 | 16 351 391 | |
2020-04-24 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −1 918 | 136 981 | −1,38 | 120,86 | −231 809 | 16 555 524 | |
2020-02-18 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −2 117 | 205 173 | −1,02 | 97,23 | −205 836 | 19 948 971 | |
2020-02-18 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −1 310 | 207 290 | −0,63 | 97,23 | −127 371 | 20 154 807 | |
2020-02-18 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −1 689 | 208 600 | −0,80 | 97,23 | −164 221 | 20 282 178 | |
2020-02-18 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
M - Exercise | −48 125 | 0 | −100,00 | ||||
2020-02-18 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
A - Award | 60 886 | 60 886 | |||||
2020-02-18 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 13 559 | 210 289 | 6,89 | ||||
2020-02-18 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −5 009 | 196 730 | −2,48 | 95,68 | −479 261 | 18 823 126 | |
2020-02-18 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 48 125 | 201 739 | 31,33 | 9,96 | 479 325 | 2 009 320 | |
2020-02-14 |
|
4 | TECH |
BIO-TECHNE Corp
Stock Option (right to buy) |
M - Exercise | −5 000 | 0 | −100,00 | ||||
2020-02-14 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
S - Sale | −5 000 | 4 021 | −55,43 | 205,23 | −1 026 132 | 825 216 | |
2020-02-14 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
M - Exercise | 5 000 | 9 021 | 124,35 | 61,46 | 307 300 | 554 431 | |
2019-12-26 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −2 948 | 153 614 | −1,88 | 105,87 | −312 105 | 16 263 114 | |
2019-12-26 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 5 946 | 156 562 | 3,95 | ||||
2019-12-26 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −3 801 | 150 616 | −2,46 | 105,87 | −402 412 | 15 945 716 | |
2019-12-26 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 7 668 | 154 417 | 5,23 | ||||
2019-10-28 |
|
4 | TECH |
BIO-TECHNE Corp
Stock Option (right to buy) |
A - Award | 2 011 | 2 011 | |||||
2019-10-28 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
A - Award | 495 | 4 021 | 14,04 | ||||
2019-09-24 |
|
4/A | LGND |
LIGAND PHARMACEUTICALS INC
0.75% Convertible Senior Notes due 2023 |
P - Purchase | 988 468,75 | ||||||
2019-09-23 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
0.75% Convertible Senior Notes due 2023 |
P - Purchase | 841 250,00 | ||||||
2019-07-31 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
P - Purchase | 1 850 | 146 749 | 1,28 | 95,45 | 176 582 | 14 007 192 | |
2019-06-06 |
|
4 | TECH |
BIO-TECHNE Corp
Stock Options (Right to buy) |
M - Exercise | −5 000 | 0 | −100,00 | ||||
2019-06-06 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
S - Sale | −5 000 | 3 526 | −58,64 | 203,67 | −1 018 346 | 718 137 | |
2019-06-06 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
M - Exercise | 5 000 | 8 526 | 141,80 | 63,03 | 315 150 | 537 394 | |
2019-05-31 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
P - Purchase | 1 000 | 144 899 | 0,69 | 108,20 | 108 202 | 15 678 362 | |
2019-05-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
P - Purchase | 2 500 | 143 899 | 1,77 | 113,50 | 283 750 | 16 332 536 | |
2019-03-15 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
P - Purchase | 2 500 | 141 399 | 1,80 | 114,29 | 285 725 | 16 160 492 | |
2019-02-13 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
A - Award | 58 596 | 58 596 | |||||
2019-02-13 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 12 809 | 138 899 | 10,16 | ||||
2019-01-25 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −3 168 | 126 090 | −2,45 | 111,78 | −354 119 | 14 094 340 | |
2019-01-25 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 6 390 | 129 258 | 5,20 | ||||
2019-01-25 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −3 597 | 122 868 | −2,84 | 111,78 | −402 073 | 13 734 185 | |
2019-01-25 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 7 256 | 126 465 | 6,09 | ||||
2019-01-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
M - Exercise | −4 000 | 0 | −100,00 | ||||
2019-01-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Incentive Stock Option (right to buy) |
M - Exercise | −29 790 | 0 | −100,00 | ||||
2019-01-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 29 790 | 119 209 | 33,32 | 16,14 | 480 811 | 1 924 033 | |
2019-01-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 4 000 | 89 419 | 4,68 | 16,14 | 64 560 | 1 443 223 | |
2018-10-29 |
|
4 | TECH |
BIO-TECHNE Corp
Stock Options (Right to buy) |
A - Award | 1 898 | 1 898 | |||||
2018-10-29 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
A - Award | 514 | 3 526 | 17,07 | ||||
2018-08-31 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | −3 500 | 85 419 | −3,94 | 258,25 | −903 875 | 22 059 457 | |
2018-08-27 |
|
4 | TECH |
BIO-TECHNE Corp
Stock Option (right to buy) |
M - Exercise | −10 000 | 0 | −100,00 | ||||
2018-08-27 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
S - Sale | −10 000 | 3 012 | −76,85 | 187,92 | −1 879 173 | 566 007 | |
2018-08-27 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
M - Exercise | 10 000 | 13 012 | 332,01 | 61,08 | 610 800 | 794 773 | |
2018-08-17 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −12 993 | 159 000 | −7,55 | |||
2018-08-17 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −12 993 | 88 919 | −12,75 | 243,00 | −3 157 299 | 21 607 317 |
2018-08-17 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | X | 12 993 | 101 912 | 14,61 | 14,47 | 188 009 | 1 474 667 |
2018-08-17 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −3 007 | 171 993 | −1,72 | |||
2018-08-17 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −21 507 | 88 919 | −19,48 | 241,33 | −5 190 261 | 21 458 724 |
2018-08-17 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | X | 3 007 | 110 426 | 2,80 | 14,47 | 43 511 | 1 597 864 |
2018-05-15 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Incentive Stock Option (right to buy) |
M - Exercise | X | −12 405 | 29 790 | −29,40 | |||
2018-05-15 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −12 405 | 107 419 | −10,35 | 179,97 | −2 232 491 | 19 331 875 |
2018-05-15 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | X | 12 405 | 119 824 | 11,55 | 16,14 | 200 217 | 1 933 959 |
2018-03-06 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −2 982 | 107 419 | −2,70 | 165,87 | −494 624 | 17 817 590 | |
2018-03-06 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 6 015 | 110 401 | 5,76 | ||||
2018-03-06 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
A - Award | 41 392 | 41 392 | |||||
2018-03-06 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 7 928 | 104 386 | 8,22 | ||||
2018-02-16 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −1 689 | 96 458 | −1,72 | 157,18 | −265 477 | 15 161 268 | |
2018-02-16 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −1 918 | 98 147 | −1,92 | 157,18 | −301 471 | 15 426 745 | |
2018-02-16 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −2 635 | 100 065 | −2,57 | 157,18 | −414 169 | 15 728 217 | |
2018-02-16 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −9 000 | 102 700 | −8,06 | 157,03 | −1 413 279 | 16 127 084 |
2018-01-26 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −22 500 | 111 700 | −16,77 | 165,00 | −3 712 500 | 18 430 500 |
2018-01-22 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Incentive Stock Option (right to buy) |
M - Exercise | X | −16 249 | 42 195 | −27,80 | |||
2018-01-22 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −11 850 | 134 200 | −8,11 | 151,92 | −1 800 307 | 20 388 281 |
2018-01-22 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −16 249 | 146 050 | −10,01 | 155,00 | −2 518 595 | 22 637 750 |
2018-01-22 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | X | 16 249 | 162 299 | 11,13 | 16,14 | 262 259 | 2 619 506 |
2017-12-29 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −5 199 | 146 050 | −3,44 | 138,66 | −720 893 | 20 251 293 | |
2017-12-29 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 9 965 | 151 249 | 7,05 | ||||
2017-11-20 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | −2 258 | 141 284 | −1,57 | 140,34 | −316 888 | 19 827 797 | |
2017-11-17 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | −5 269 | 143 542 | −3,54 | 142,53 | −750 991 | 20 459 041 | |
2017-10-30 |
|
4 | TECH |
BIO-TECHNE Corp
Stock Option (right to buy) |
A - Award | 3 125 | 3 125 | |||||
2017-10-30 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
A - Award | 739 | 3 012 | 32,51 | ||||
2017-10-17 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Incentive Stock Option (right to buy) |
M - Exercise | −11 384 | 0 | −100,00 | ||||
2017-10-17 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −1 744 | 148 811 | −1,16 | 143,04 | −249 462 | 21 285 925 | |
2017-10-17 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 11 384 | 150 555 | 8,18 | 21,92 | 249 537 | 3 300 166 | |
2017-09-06 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Incentive Stock Option (right to buy) |
M - Exercise | −5 000 | 0 | −100,00 | ||||
2017-09-06 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −5 000 | 139 171 | −3,47 | 130,00 | −650 000 | 18 092 230 |
2017-09-06 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | X | 5 000 | 144 171 | 3,59 | 21,00 | 105 000 | 3 027 591 |
2017-08-10 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Incentive Stock Option (right to buy) |
M - Exercise | X | −5 483 | 5 000 | −52,30 | |||
2017-08-10 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −5 483 | 139 171 | −3,79 | 125,00 | −685 375 | 17 396 375 |
2017-08-10 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | X | 5 483 | 144 654 | 3,94 | 21,00 | 115 143 | 3 037 734 |
2017-06-23 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | X | −4 666 | 0 | −100,00 | |||
2017-06-23 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −4 666 | 139 171 | −3,24 | 120,00 | −559 920 | 16 700 520 |
2017-06-23 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | X | 4 666 | 143 837 | 3,35 | 21,00 | 97 986 | 3 020 577 |
2017-06-23 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
A - Award | 4 666 | 4 666 | |||||
2017-06-09 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Incentive Stock Option (right to buy) |
M - Exercise | X | −12 000 | 10 483 | −53,37 | |||
2017-06-09 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −12 000 | 139 171 | −7,94 | 114,87 | −1 378 440 | 15 986 573 |
2017-06-09 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | X | 12 000 | 151 171 | 8,62 | 21,00 | 252 000 | 3 174 591 |
2017-03-21 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −4 000 | 139 171 | −2,79 | 109,10 | −436 400 | 15 183 556 |
2017-03-10 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Incentive Stock Option (right to buy) |
M - Exercise | −15 675 | 0 | −100,00 | ||||
2017-03-10 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −1 473 | 143 171 | −1,02 | 106,92 | −157 493 | 15 307 843 | |
2017-03-10 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 15 675 | 144 644 | 12,15 | 10,05 | 157 534 | 1 453 672 | |
2017-03-10 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | −4 000 | 128 969 | −3,01 | 107,06 | −428 240 | 13 807 421 | |
2017-02-28 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
A - Award | 43 646 | 43 646 | |||||
2017-02-28 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 10 224 | 132 969 | 8,33 | ||||
2017-02-28 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −4 783 | 122 745 | −3,75 | 100,38 | −480 118 | 12 321 143 | |
2017-02-28 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 9 168 | 127 528 | 7,75 | ||||
2017-02-28 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −2 019 | 118 360 | −1,68 | 104,28 | −210 541 | 12 342 581 | |
2017-02-28 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −2 285 | 120 379 | −1,86 | 104,28 | −238 280 | 12 553 122 | |
2016-10-31 |
|
4 | TECH |
BIO-TECHNE Corp
Stock Option (right to buy) |
A - Award | 3 985 | 3 985 | |||||
2016-10-31 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
A - Award | 914 | 2 273 | 67,26 | ||||
2016-09-23 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | −3 000 | 122 664 | −2,39 | 117,34 | −352 020 | 14 393 394 | |
2016-09-12 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
S - Sale | −1 700 | 1 359 | −55,57 | 109,83 | −186 716 | 149 263 | |
2016-03-09 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Incentive Stock Option (right to buy) |
M - Exercise | −6 000 | 22 483 | −21,07 | ||||
2016-03-09 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 6 000 | 125 664 | 5,01 | 21,00 | 126 000 | 2 638 944 | |
2016-03-09 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | −556 | 119 664 | −0,46 | 102,97 | −57 251 | 12 321 802 | |
2016-03-09 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | −10 277 | 120 220 | −7,88 | 102,44 | −1 052 776 | 12 315 337 | |
2016-02-16 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −2 492 | 130 497 | −1,87 | 85,97 | −214 237 | 11 218 827 | |
2016-02-16 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
A - Award | 55 391 | 55 391 | |||||
2016-02-16 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 11 611 | 132 989 | 9,57 | ||||
2015-11-02 |
|
4 | TECH |
BIO-TECHNE Corp
Stock Option (Right to Buy) |
A - Award | 4 260 | 4 260 | |||||
2015-11-02 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
A - Award | 1 059 | 3 059 | 52,95 | ||||
2015-08-07 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | −4 666 | 121 378 | −3,70 | 110,79 | −516 946 | 13 447 469 | |
2015-06-11 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | −500 | 126 044 | −0,40 | 95,06 | −47 530 | 11 981 743 | |
2015-06-11 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | −3 300 | 126 544 | −2,54 | 93,21 | −307 593 | 11 795 166 | |
2015-06-11 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | −6 200 | 129 844 | −4,56 | 92,53 | −573 686 | 12 014 465 | |
2015-02-11 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
A - Award | 56 198 | 56 198 | 56,26 | 3 161 699 | 3 161 699 | ||
2015-02-11 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 15 945 | 136 044 | 13,28 | ||||
2014-11-03 |
|
4 | TECH |
BIO-TECHNE Corp
Stock Option (right to buy) |
A - Award | 4 000 | 4 000 | |||||
2014-11-03 |
|
4 | TECH |
BIO-TECHNE Corp
Common Stock |
A - Award | 1 000 | 2 000 | 100,00 | ||||
2014-08-15 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
P - Purchase | 1 000 | 120 099 | 0,84 | 54,97 | 54 970 | 6 601 842 | |
2014-02-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −16 875 | 48 125 | −25,96 | |||
2014-02-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
A - Award | 10 000 | 95 000 | 11,76 | 74,42 | 744 200 | 7 069 900 | |
2014-02-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
A - Award | 10 000 | 95 000 | 11,76 | 74,42 | 744 200 | 7 069 900 | |
2014-02-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
A - Award | 75 000 | 75 000 | 74,42 | 5 581 500 | 5 581 500 | ||
2014-02-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 8 000 | 119 099 | 7,20 | ||||
2014-02-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −16 875 | 111 099 | −13,19 | 75,00 | −1 265 625 | 8 332 425 |
2014-02-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 16 875 | 127 974 | 15,19 | 9,96 | 168 075 | 1 274 621 | |
2014-01-21 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Incentive Stock Option (right to buy) |
M - Exercise | −9 000 | 28 483 | −24,01 | 21,00 | −189 000 | 598 143 | |
2014-01-21 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 9 000 | 111 099 | 8,81 | 21,00 | 189 000 | 2 333 079 | |
2014-01-21 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −15 000 | 102 099 | −12,81 | 64,00 | −960 000 | 6 534 336 |
2013-11-04 |
|
4 | TECH |
TECHNE CORP /MN/
Stock Option |
A - Award | 4 000 | 4 000 | |||||
2013-11-04 |
|
4 | TECH |
TECHNE CORP /MN/
Common Stock |
A - Award | 1 000 | 1 000 | |||||
2013-10-22 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Incentive Stock Option (right to buy) |
M - Exercise | −5 850 | 37 483 | −13,50 | ||||
2013-10-22 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Incentive Stock Option (right to buy) |
M - Exercise | −4 668 | 15 675 | −22,95 | ||||
2013-10-22 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 4 668 | 117 099 | 4,15 | 10,05 | 46 913 | 1 176 845 | |
2013-10-22 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 5 850 | 112 431 | 5,49 | 21,00 | 122 850 | 2 361 051 | |
2013-10-22 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −10 000 | 106 581 | −8,58 | 55,00 | −550 000 | 5 861 955 |
2013-08-20 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Incentive Stock Option (right to buy) |
M - Exercise | −6 556 | 58 444 | −10,09 | ||||
2013-08-20 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 6 556 | 116 581 | 5,96 | 16,14 | 105 814 | 1 881 617 | |
2013-08-20 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | −10 000 | 110 025 | −8,33 | 42,85 | −428 500 | 4 714 571 | |
2013-06-04 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
A - Award | 14 334 | 14 334 | 32,00 | 458 688 | 458 688 | ||
2013-06-04 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 12 000 | 120 025 | 11,11 | ||||
2013-06-04 |
|
4/A | LGND |
LIGAND PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
A - Award | 160 666 | 160 666 | 14,47 | 2 324 837 | 2 324 837 | ||
2013-06-04 |
|
4/A | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 6 000 | 95 275 | 6,72 | ||||
2013-02-19 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
A - Award | 95 616 | 95 616 | 21,92 | 2 095 903 | 2 095 903 | ||
2013-02-19 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Incentive Stock Option (right to buy) |
A - Award | 11 384 | 11 384 | 21,92 | 249 537 | 249 537 | ||
2013-02-19 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 8 000 | 120 025 | 7,14 | ||||
2012-12-05 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
P - Purchase | 2 000 | 112 025 | 1,82 | 18,03 | 36 060 | 2 019 811 | |
2012-10-26 |
|
4 | TECH |
TECHNE CORP /MN/
Stock Option |
A - Award | 5 000 | 5 000 | |||||
2012-08-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
P - Purchase | 500 | 110 025 | 0,46 | 16,39 | 8 195 | 1 803 310 | |
2012-07-03 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
J - Other | 1 250 | 109 525 | 1,15 | 10,12 | 12 654 | 1 108 776 | |
2012-05-25 |
|
4 | BCRX |
BIOCRYST PHARMACEUTICALS INC
Automatic Stock Option Grant |
A - Award | 15 000 | 15 000 | |||||
2012-05-08 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
P - Purchase | 1 000 | 108 275 | 0,93 | 12,04 | 12 040 | 1 303 631 | |
2012-02-13 |
|
4 | LGNDD |
LIGAND PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
A - Award | 175 000 | 175 000 | 14,47 | 2 532 250 | 2 532 250 | ||
2012-02-13 |
|
4 | LGNDD |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 18 000 | 107 275 | 20,16 | ||||
2012-01-06 |
|
4 | LGNDD |
LIGAND PHARMACEUTICALS INC
Common Stock |
J - Other | 210 | 89 275 | 0,24 | 10,09 | 2 119 | 900 740 | |
2004-05-18 | 3/A | BCRX |
BIOCRYST PHARMACEUTICALS INC
None |
0 |